Albireo Pharma, Inc. announced the appointments of Habib Dable and Susan Alesina to its Board of Directors — two experienced, strategic leaders with vast pharmaceutical and biotech expertise in business development, operations and commercialization. These additions mark an exciting time for Albireo as it continues to deliver on its clinical, regulatory, and commercialization milestones for Bylvay® (odevixibat) and advance additional investigational compounds for adult liver and viral diseases. Mr. Dable is a versatile, patient-focused executive with approximately 28 years in “Big Pharma” and “Emerging Biotech” environments, currently an Independent Director at Blueprint Medicines Corporation and part-time Venture Partner at RA Ventures.

Most recently, Mr. Dable was President & CEO of Acceleron Pharma Inc., a biopharmaceutical company targeting therapies for patients with serious and rare diseases until its sale to Merck in 2021 for $11.5B. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG. During his tenure at Bayer, Mr. Dable held positions of increasing responsibility, including President of U.S. Pharmaceuticals, Executive Vice President, Global Head Specialty Medicine.

Mr. Dable led the launch of various blockbuster brands, including EYLEA®, Stivarga®, and Xofigo®. Mr. Dable is a previous member of the Board of Directors for BIO (Biotechnology Innovation Organization) and a prior Independent Board Director for Millendo Therapeutics. Mr. Dable holds a Master's and Bachelor's degree in business administration from the University of New Brunswick and completed an executive program from Stanford University's Graduate School of Business.

Ms. Alesina has more than 25 years of management experience in pharmaceutical, biotech, and medical device organizations. Throughout her career, she held senior roles in strategic planning and analysis, business development, and communications. She currently serves as Vice President, National Business Development and Alliances at Boston Children's Hospital, where she leads efforts to identify and develop strategic partnerships with national health systems and hospital providers to improve access for pediatric patients with rare and complex conditions.

Previously, she was Global Head of Business Partners Communications at Millipore Sigma and, prior to that, served as a business consultant for pharmaceutical companies as well as had various leadership roles in corporate planning and communications at Sunovion Pharmaceuticals Inc. During her tenure at Sunovion, Ms. Alesina supported the launch of blockbuster products including Lunesta® and Latuda®. Ms. Alesina is a past board member of the Thompson Island Outward Bound Education Center, St. Mark's School of Southborough, MA, and the Boston Chapter of the Healthcare Businesswomen's Association, where she was also the president.

She is currently a board member for the HBS Healthcare Alumni Association. Ms. Alesina holds a Bachelor's degree from the University of North Carolina at Chapel Hill, where she was a Morehead-Cain Scholar, and an M.B.A. from Harvard Business School.